Nice-Systems Ltd (NICE.TA)

NICE.TA on Tel Aviv Stock Exchange

19,310.00
29 Jan 2015
Change (% chg)

-560.00₪ (-2.82%)
Prev Close
19,870.00₪
Open
19,430.00₪
Day's High
19,500.00₪
Day's Low
19,310.00₪
Volume
276,841
Avg. Vol
96,663
52-wk High
20,330.00₪
52-wk Low
13,060.00₪

NICE.TA

Chart for NICE.TA

About

Nice Systems Ltd (NICE) is a provider of solutions that enable enterprises and security organizations to extract insight from interactions, transactions and surveillance. Its solutions enable companies and public organizations to capture, manage, analyze and impact unstructured interaction, as well as transactional data,... (more)

Overall

Beta: 0.91
Market Cap(Mil.): ₪11,754.09
Shares Outstanding(Mil.): 60.95
Dividend: 61.24
Yield (%): 1.27

Financials

  NICE.TA Industry Sector
P/E (TTM): 64.55 28.23 20.32
EPS (TTM): 2.99 -- --
ROI: 4.20 17.61 14.20
ROE: 4.38 18.12 11.37
Search Stocks

Israel's Nice Systems Q3 profit, revenue gain

JERUSALEM, Nov 5 - Israeli software provider Nice Systems reported higher quarterly profit that handily topped estimates, boosted by growth in its analytic applications.

05 Nov 2014

UK cost agency NICE rejects another Roche cancer drug

LONDON - Another new cancer drug from Roche, this time for treating leukaemia, has been rejected by Britain's healthcare cost-effectiveness agency NICE on the grounds that data about its value is uncertain.

02 Oct 2014

UK cost agency NICE rejects another Roche cancer drug

LONDON, Oct 3 - Another new cancer drug from Roche , this time for treating leukaemia, has been rejected by Britain's healthcare cost-effectiveness agency NICE on the grounds that data about its value is uncertain.

02 Oct 2014

GSK melanoma pill backed by UK cost watchdog with price cut

LONDON - Britain's healthcare cost agency NICE has recommended a third new drug for melanoma, this time from GlaxoSmithKline, after the drugmaker offered to supply it at a discount to the state-run National Health Service.

17 Sep 2014

GSK melanoma pill backed by UK cost watchdog with price cut

LONDON, Sept 18 - Britain's healthcare cost agency NICE has recommended a third new drug for melanoma, this time from GlaxoSmithKline, after the drugmaker offered to supply it at a discount to the state-run National Health Service.

17 Sep 2014

Earnings vs. Estimates

Search Stocks